Prozkoumejte nejčtenější články a videa na Campus Sanofi
LIBERTY AD SOLO-CONTINUE was a randomized, double-blind, phase 3 clinical trial at 185 sites in North America, Europe, Asia, and Japan.
LIBERTY AD HAFT was a randomized phase 3 trial in adults and adolescents with moderate-to-severe hand and foot atopic dermatitis inadequately controlled with topicals.
Efficacy is shown through real-world evidence, skin bacterial microbiome, trans-epidermal water loss (TEWL), and nonatopic comorbidities.
Significant improvement in Worst Scratch and Itch NRS score, Skin Clearance, and Children’s Dermatology Life Quality Index (CDLQI).
Efficacy is shown through 3 years of disease control, impact on growth curve, and improvement in mental health.
“Vakalarla Toujeo’ya Geçiş”, diyabet tedavisinde Toujeo’ya geçişi gerçek hasta vakaları ve hekim deneyimleriyle ele alan, pratik klinik içgörüler sunan bir video serisidir.